Stem Cell Politics and Progressive Values
By Marcy Darnovsky,
reprint of talk at Take Back America 2006
| 06. 15. 2006
Presentation at Take Back America conference, Washington, DC
My remarks today are about progressive values and the politics of stem cell research, and I have some things to tell you that you may not expect.
We all know that the Bush limits on federal funding of embryonic stem cell research are another case of pandering to the religious right, and we look forward to those restrictions being lifted in a Senate vote soon. And we all hope that stem cell research results in new scientific understandings and new medical treatments.
But if our analysis and understanding were to stop there, we’d be overlooking a number of very important progressive values that we urgently need to bring to the politics of stem cell research. If we continue to let the Right frame stem cell research as simply a question about the moral status of embryos, if we buy into the black-and-white polarized politics that has too often characterized the stem cell debate, we’ll be selling ourselves and our values short, and missing important political opportunities.
My organization, the Center for Genetics...
Related Articles
By Priyanka Runwal, Chemical and Engineering News | 08.05.2024
Saritee Sanodiya, 26, has spent countless days wondering if she’ll ever live a “normal” life. Growing up, Sanodiya often missed school, frequenting the hospital for sudden, life-threatening drops in her hemoglobin levels and excruciating pain in her joints. High fever...
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Sarah Kliff and Azeen Ghorayshi, The New York Times | 07.15.2024